CSF2 and prostate cancer: A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/​F +/​- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Prospect)